natgillin/translations-raw huggingface dataset:
Your doctor may decide if you or the child need less anti-diabetic medicine while taking LIFMIOR.
Zdravnik lahko odloči, da boste vi ali otrok med jemanjem zdravila LIFMIOR potrebovali manj zdravila za zdravljenje sladkorne bolezni.
There is generally no applicable use of LIFMIOR in children aged below 2 years in the indication juvenile idiopathic arthritis.
Zdravila LIFMIOR se običajno ne uporablja za zdravljenje juvenilnega idiopatskega artritisa pri otrocih, mlajših od 2 let.
• Infections/surgery: If you or the child develop a new infection, or are about to have any major surgery, your doctor may wish to monitor the treatment with LIFMIOR.
Okužbe/operacije: Če se pri vas ali otroku pojavi nova okužba ali če je pri vas ali otroku predvidena kakršnakoli večja operacija, bo zdravnik morda želel spremljati zdravljenje z zdravilom LIFMIOR.
Side effects in children and adolescents
Neželeni učinki pri otrocih in mladostnikih
Do not attempt to administer an injection until you are sure that you understand how to use the MYCLIC pen properly.
Dokler niste povsem prepričani, da razumete, kako je treba pravilno uporabljati peresnik MYCLIC, ne poskušajte injicirati zdravila.
16 alcohol swabs
16 alkoholnih blazinic
The syringe inside the pen is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic plunger.
Injekcijska brizga v peresniku je izdelana iz prozornega stekla tipa I z iglo velikosti 27 iz nerjavečega jekla, gumijastim pokrovčkom igle in plastičnim batom.
The three recommended injection sites for LIFMIOR using a pre-filled syringe include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 1).
Za injiciranje napolnjene injekcijske brizge zdravila LIFMIOR so priporočljiva tri injekcijska mesta: (1) na sredini sprednjega dela stegna; (2) na trebuhu, razen v predelu 5 cm okrog popka; in (3) na zunanjem delu nadlakti (glejte sliko 1).
Step 3: Injecting the LIFMIOR solution
Korak 3: Injiciranje raztopine zdravila LIFMIOR
Pruritus, rash Angioedema, psoriasis (including new onset or worsening and pustular, primarily palms and soles), urticaria, psoriasiform rash
Bolezni kože in podkožja pruritus, izpuščaj angioedem, psoriaza (vključno s tako, ki se začne na novo ali se poslabša, in pustularno, predvsem na dlaneh in podplatih), urtikarija, psoriaziformen izpuščaj
Among patients receiving LIFMIOR, the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly always occurred by 3 months.
Pri bolnikih na zdravilu LIFMIOR se je klinični odziv običajno pojavil že v prvem ali drugem tednu zdravljenja, skoraj vedno pa je nastopil do 3. meseca.
Solution for injection in a pre-filled pen (MYCLIC)
raztopina za injiciranje v napolnjenem injekcijskem peresniku (MYCLIC)
Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
Zdravljenje hude kronične psoriaze v plakih pri otrocih in mladostnikih od 6. leta starosti naprej, pri katerih se z drugo sistemsko terapijo ali fototerapijo bolezni ne da zadostno obvladati ali jih bolniki ne prenašajo.
This injection should not be mixed in the same syringe or vial with any other medicine.
Tega zdravila ne smete mešati z drugimi zdravili v isti injekcijski brizgi ali viali.
Additionally, some patients developed recall injection site reactions characterised by a skin reaction at the most recent site of injection, along with the simultaneous appearance of injection site reactions at previous injection sites.
Poleg tega so nekateri bolniki dobili tako imenovano spominsko lokalno reakcijo na mestu injiciranja; ob naslednjem injiciranju se je poleg reakcije na tedanjem mestu injiciranja sočasno pojavila reakcija tudi na prejšnjih mestih injiciranja.
The safety and efficacy of 50 mg LIFMIOR (two 25 mg SC injections) administered once weekly were evaluated in a double-blind, placebo-controlled study of 420 patients with active RA.
Varnost in učinkovitost 50 mg zdravila LIFMIOR (dve subkutani injekciji po 25 mg) enkrat na teden so ocenili v dvojno slepi, s placebom nadzorovani študiji pri 420 bolnikih z aktivnim revmatoidnim artritisom.
*Some patients did not provide complete data for each endpoint **ASAS=Assessments in Spondyloarthritis International Society ***Bath Ankylosing Spondylitis Disease Activity Index a: p <0.001, b:<0.01 and c:<0.05, respectively between LIFMIOR and placebo
** ASAS = Mednarodno združenje za ocenjevanje spondilartritisa *** Indeks Bath za ocenjevanje aktivnosti ankilizirajočega spondilitisa a: p < 0,001, b: < 0,01 oziroma c: < 0,05 med zdravilom LIFMIOR in placebom
When reconstituted, the solution contains 10 mg/ml of etanercept.
Po rekonstituciji raztopina vsebuje 10 mg/ml etanercepta.
ACR 50 Month 3
ACR 50 3. mesec 6. mesec
The active ingredient in LIFMIOR is etanercept.
Učinkovina zdravila LIFMIOR je etanercept.
• The three recommended injection sites for LIFMIOR include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 17).
Za injiciranje zdravila LIFMIOR so priporočljiva tri injekcijska mesta: (1) na sredini sprednjega dela stegna; (2) na trebuhu, razen v predelu 5 cm okrog popka; in (3) na zunanjem delu nadlakti (glejte sliko 17).
Step 1: Setting up for an injection
Korak 1: Priprava na injiciranje
Adult patients with psoriatic arthritis
Odrasli bolniki s psoriatičnim artritisom
Study 2
Študija 2
This injection should not be mixed with any other medicine.
Tega zdravila ne smete mešati z drugimi zdravili.
However, any of the above symptoms may indicate an allergic reaction to LIFMIOR, so you should seek immediate medical attention.
Resne alergijske reakcije so redke, vendar pa lahko katerikoli od zgoraj navedenih simptomov kaže na pojav alergijske reakcije na zdravilo LIFMIOR, zato morate nemudoma poiskati zdravniško pomoč.
Your doctor will determine if LIFMIOR is an appropriate treatment.
Zdravnik bo presodil o primernosti zdravljenja z zdravilom LIFMIOR.
The dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly.
Odmerek naj bo 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden.
Step 1: Preparing for an LIFMIOR injection
Korak 1: Priprava na injiciranje zdravila LIFMIOR
The efficacy of LIFMIOR was compared to methotrexate in a randomised, active-controlled study with blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid arthritis (<3 years duration) who had never received treatment with methotrexate.
V randomizirani študiji, nadzorovani z učinkovino, so s slepo radiografsko oceno kot primarnim opazovanim dogodkom primerjali učinkovitost zdravila LIFMIOR z učinkovitostjo metotreksata pri 632 odraslih bolnikih z aktivnim revmatoidnim artritisom (trajanje bolezni manj kot 3 leta), ki se pred tem nikoli niso zdravili z metotreksatom.
At 24 weeks, 56% of patients in the LIFMIOR-treated group had achieved the PASI 75 compared to 5% of placebo-treated patients.
V 24. tednu je 56 % bolnikov doseglo PASI 75 v skupini, zdravljeni z zdravilom LIFMIOR, v skupini s placebom pa 5 % bolnikov.
Your doctor may decide to continue to monitor you or the child for the presence of infections after you or the child stop using LIFMIOR.
Vaš zdravnik se bo morda odločil, da bo vas ali vašega otroka tudi po koncu zdravljenja z zdravilom LIFMIOR spremljal glede prisotnosti okužb.
LIFMIOR may be stored at temperatures up to a maximum of 25° C for a single period of up to four weeks; after which, it should not be refrigerated again.
Zdravilo LIFMIOR se lahko shranjuje pri temperaturi do največ 25 °C za enkratno obdobje do štirih tednov, po katerem se ga ne sme več ohladiti.
Severe adverse events reported included varicella with signs and symptoms of aseptic meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.
Hudi neželeni učinki, o katerih so poročali, so bili: norice z znaki in simptomi aseptičnega meningitisa, ki je izzvenel brez posledic (glejte tudi poglavje 4.4), vnetje slepiča, gastroenteritis, depresija/osebnostne motnje, kožne razjede, ezofagitis/gastritis, streptokokni septični šok (streptokoki skupine A), sladkorna bolezen tipa I in okužbe mehkih tkiv ter postoperativnih ran.
• Latex: The needle cover is made from latex (dry natural rubber).
Lateks: Pokrovček igle je izdelan iz lateksa (suhega naravnega kavčuka).
Before injection, LIFMIOR single-use pre-filled syringe should be allowed to reach room temperature (approximately 15 to 30 minutes).
Pred injiciranjem je treba napolnjene injekcijske peresnike zdravila LIFMIOR za enkratno uporabo segreti na sobno temperaturo (počakati približno 15 do 30 minut).
24 pre-filled syringes 24 alcohol swabs
24 napolnjenih injekcijskih brizg 24 alkoholnih blazinic
• Cancer: Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or any other cancer before you are given LIFMIOR.
Rak: Preden boste prejeli zdravilo LIFMIOR, povejte zdravniku, če imate ali ste kdaj imeli limfom (vrsta krvnega raka) ali drugo obliko raka.
Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal infections, listeriosis and legionellosis, have been reported with the use of LIFMIOR (see section 4.8).
Pri uporabi zdravila LIFMIOR so poročali o primerih resnih okužb, sepse, tuberkuloze in oportunističnih okužb, vključno z invazivnimi glivičnimi okužbami, listeriozo in legionelozo (glejte poglavje 4.8).
The results are shown in the figure below.
Izsledki so predstavljeni na spodnji sliki.
In a controlled clinical trial of two years duration in adult rheumatoid arthritis patients, the combination of LIFMIOR and methotrexate did not result in unexpected safety findings, and the safety profile of LIFMIOR when given in combination with methotrexate was similar to the profiles reported in studies of LIFMIOR and methotrexate alone.
V dveletnem nadzorovanem kliničnem preskušanju pri odraslih bolnikih z revmatoidnim artritisom ni bilo pri kombiniranem zdravljenju z zdravilom LIFMIOR in metotreksatom nobenih nepričakovanih ugotovitev glede varnosti; varnostni profil zdravila LIFMIOR pri kombiniranem zdravljenju z metotreksatom je bil podoben varnostnemu profilu, ki je bil ugotovljen pri monoterapiji z zdravilom LIFMIOR oziroma metotreksatom.
Non-radiographic axial spondyloarthritis
Radiografsko nezaznavni aksialni spondilartritis
The safety and efficacy profiles of the 50 mg once weekly and 25 mg twice weekly regimens were similar.
Profil varnosti in učinkovitosti je bil pri režimu dajanja 50 mg enkrat na teden podoben kot pri režimu dajanja 25 mg dvakrat na teden.
LIFMIOR is available in strengths of 10, 25 and 50 mg.
Zdravilo LIFMIOR je na voljo v jakostih 10, 25 in 50 mg.
Clinical responses among nr-AxSpa patients who received LIFMIOR were apparent at the time of the first visit (2 weeks) and were maintained through 2 years of therapy.
Klinični odzivi pri bolnikih z nr-AxSpa, ki so prejemali LIFMIOR, so bili vidni ob prvem obisku (po 2 tednih) in so se vzdrževali med celotnim 2-letnim zdravljenjem.
• Place the filled syringe on the clean, flat surface.
Napolnjeno injekcijsko brizgo položite na čisto in ravno površino.
Purple needle safety shield extends to cover needle
Vijolični varnostni ščit igle se podaljša in prekrije iglo.
If you are not sure, please talk to your doctor.
Če ste v dvomih, se posvetujte z zdravnikom.
Your doctor will determine if preventive treatment for chickenpox is appropriate.
Zdravnik bo presodil, ali je potrebno preventivno zdravljenje proti noricam.
In another open-label single-arm study, 60 patients with extended oligoarthritis (15 patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17 years old), 38 patients with enthesitis-related arthritis (12 to 17 years old), and 29 patients with psoriatic arthritis (12 to 17 years old) were treated with LIFMIOR at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose) administered weekly for 12 weeks.
V drugi odprti študiji z eno skupino se je z zdravilom LIFMIOR v odmerku 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden zdravilo 60 bolnikov z razširjenim oligoartritisom (15 bolnikov, starih od 2 do 4 leta, 23 bolnikov, starih od 5 do 11 let, in 22 bolnikov, starih od 12 do 17 let), 38 bolnikov z artritisom, povezanim z entezitisom (starih od 12 do 17 let) in 29 bolnikov s psoriatičnim artritisom (starih od 12 do 17 let).
Patients in this study received a dose of 25 mg or 50 mg LIFMIOR, or placebo twice a week for 12 weeks and then all patients received open-label 25 mg LIFMIOR twice weekly for an additional 24 weeks.
Bolniki v tej študiji so dobivali odmerek 25 mg ali 50 mg zdravila LIFMIOR ali placebo dvakrat na teden 12 tednov, potem pa so vsi bolniki v odprtem delu dobivali 25 mg zdravila LIFMIOR dvakrat na teden dodatnih 24 tednov.
In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of LIFMIOR and methotrexate did not result in unexpected safety findings, and the safety profile of LIFMIOR when given in combination with methotrexate was similar to the profiles reported in studies of LIFMIOR and methotrexate alone.
V dveletnem nadzorovanem kliničnem preskušanju pri bolnikih z revmatoidnim artritisom ni bilo pri kombiniranem zdravljenju z zdravilom LIFMIOR in metotreksatom nobenih nepričakovanih ugotovitev glede varnosti; varnostni profil zdravila LIFMIOR pri kombiniranem zdravljenju z metotreksatom je bil podoben varnostnemu profilu, ki je bil ugotovljen pri monoterapiji z zdravilom LIFMIOR oziroma metotreksatom.
Etanercept is a competitive inhibitor of TNF-binding to its cell surface receptors and thereby inhibits the biological activity of TNF.
Etanercept je kompetitivni antagonist vezave TNF na receptorje na površini celice in torej zavira biološko aktivnost TNF.
Pre-filled pen (MYCLIC) containing a pre-filled syringe of LIFMIOR.
Napolnjen injekcijski peresnik (MYCLIC), ki vsebuje napolnjeno injekcijsko brizgo zdravila LIFMIOR.
Withdrawing the LIFMIOR solution from the vial
Jemanje raztopine zdravila LIFMIOR iz viale
Abbreviation: sPGA-static Physician Global Assessment a. p < 0.0001 compared with placebo
sPGA “čisto” ali “minimalno”, n (%) Okrajšava: sPGA-statična zdravnikova splošna ocena a. p < 0,0001 v primerjavi s placebom
The efficacy of LIFMIOR in ankylosing spondylitis was assessed in 3 randomised, double-blind studies comparing twice weekly administration of 25 mg LIFMIOR with placebo.
Učinkovitost zdravila LIFMIOR pri bolnikih z ankilozirajočim spondilitisom je bila ocenjena v 3 randomiziranih dvojno slepih študijah, kjer so primerjali uporabo 25 mg zdravila LIFMIOR dvakrat tedensko s placebom.
Responses were measured using the ACR Pedi 30 ), defined as ≥ 30% improvement in at least three of six and ≥ 30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR).
Odzive so merili po lestvici ACR Pedi 30; izboljšanje je bilo določeno kot  30 % izboljšanje v vsaj treh od šestih glavnih kazalcev aktivnosti bolezni JRA in  30 % poslabšanje največ enega od šestih glavnih kazalcev aktivnosti bolezni JRA (število aktivno prizadetih sklepov, omejenost gibanja, zdravnikova splošna ocena, splošna ocena s strani bolnika ali staršev, ocena funkcionalnosti in hitrost sedimentacije eritrocitov).
Similarly, the significant advantages for LIFMIOR monotherapy compared with methotrexate monotherapy were also observed after 24 months.
Podobno so po 24 mesecih ugotovili tudi pomembne prednosti monoterapije z zdravilom LIFMIOR pred monoterapijo z metotreksatom.
Your symptoms may return upon discontinuation.
Po prekinitvi uporabe se lahko vaši simptomi ponovijo.
There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates risk estimation.
Pri bolnikih, ki imajo revmatoidni artritis z dolgotrajno in zelo aktivno vnetno boleznijo, je osnovno tveganje za pojav limfomov in levkemije povečano, kar oteži oceno tveganja.
The recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to 24 weeks.
Priporočeni odmerek je 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden do največ 24 tednov.
Do not touch the needle or allow it to touch any surface.
Igle se ne dotikajte in pazite, da ne pride v stik z ničemer.
Radiographic Progression: Comparison of LIFMIOR vs Methotrexate in Patients with RA of <3 Years Duration
Radiografsko napredovanje: primerjava zdravila LIFMIOR z metotreksatom pri bolnikih z RA, ki je trajal < 3 leta
LIFMIOR should not normally be used in children with polyarthritis or extended oligoarthritis below the age of 2 years, or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12 years, or in children with psoriasis below the age of 6 years.
Pri otrocih s poliartritisom ali z razširjenim oligoartritisom, mlajših od 2 let, otrocih z artritisom, povezanim z entezitisom, ali s psoriatičnim artritisom, mlajših od 12 let, in otrocih s psoriazo, mlajših od 6 let, se zdravila LIFMIOR običajno ne sme uporabljati.
For children, remove only the portion of liquid as directed by your child's doctor.
Za odraslega bolnika izvlecite celotni volumen raztopine, za otroka pa le toliko, kot je določil njegov zdravnik.
Infection (including upper respiratory tract infection, bronchitis, cystitis, skin infection)*
Infekcijske in parazitske bolezni okužba (vključno z okužbo zgornjih dihal, bronhitisom, cistitisom in okužbo kože)*
Study 3
Študija 3
Autoantibodies
Tvorba avtoprotiteles
Lightly pinching the skin around the injection site between the thumb and index finger of your free hand may make the injection easier and more comfortable.
Injiciranje utegne biti enostavnejše in manj neprijetno, če boste okoli mesta injiciranja s prosto roko narahlo stisnili kožo s palcem in kazalcem.
Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-antagonists, including LIFMIOR, has been reported.
Pri bolnikih, ki so kdaj že bili okuženi z virusom hepatitisa B (HBV) in so se zdravili z antagonisti TNF, vključno z zdravilom LIFMIOR, so poročali o reaktivaciji hepatitisa B. Poročila vključujejo tudi reaktivacijo hepatitisa B pri anti-HBc pozitivnih, vendar HBsAg negativnih bolnikih.
• To open the plastic container, hold the short, wide end in one hand.
Plastično embalažo odprete tako, da z eno roko primete za krajši, širši del. Z drugo roko pa primete za daljši del embalaže.
8 pre-filled syringes 8 alcohol swabs
8 napolnjenih injekcijskih brizg 8 alkoholnih blazinic
During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to LIFMIOR.
Med obdobjem randomiziranega prekinjanja zdravljenja se je recidiv bolezni (izguba odziva PASI 75) pojavil pri pomembno več bolnikih, ki so bili ponovno v skupini s placebom, kot pri bolnikih, ki so bili ponovno v skupini z zdravilom LIFMIOR.
Doing so could cause the liquid to leak out.
V tem primeru lahko pride do uhajanja tekočine iz brizge.
The MYCLIC pen contains a clear, colourless to pale yellow or pale brown, solution for injection.
Injekcijski peresnik MYCLIC vsebuje bistro, brezbarvno do bledo rumeno oziroma bledo rjavo raztopino za injiciranje.
The syringes are type I glass.
Brizge so steklene (steklo tipa I).
The efficacy of LIFMIOR in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was assessed in a randomised, 12-week double-blind, placebo-controlled study.
Odrasli bolniki z radiografsko nezaznavnim aksialnim spondilartritisom Učinkovitost zdravila LIFMIOR so pri bolnikih z radiografsko nezaznavnim aksialnim spondilartritisom (nr-AxSpa) ocenili v randomizirani 12-tedenski, dvojno slepi, s placebom nadzorovani študiji.
If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately.
Če se med zdravljenjem ali po njem pojavijo simptomi tuberkuloze (na primer trdovraten kašelj, hujšanje, apatija, blaga vročina) ali kakšne druge okužbe, to nemudoma povejte zdravniku.
Do not mix the LIFMIOR solution with any other medicine.
Raztopine zdravila LIFMIOR ne smete mešati z nobenim drugim zdravilom.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2)
Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
• While holding the syringe upright, remove any air bubbles by slowly pushing on the plunger until the air is removed (see Diagram 16).
Brizgo obrnite navzgor in odstranite zrak iz nje tako, da počasi pritiskate na bat, dokler ni odstranjen ves zrak (glejte sliko 16).
Doses of 10 mg or 25 mg LIFMIOR were administered subcutaneously (SC) twice a week for up to 24 months.
Odmerki 10 mg ali 25 mg zdravila LIFMIOR so bili dani subkutano (s.c.) 2-krat tedensko do 24 mesecev.
After taking a syringe from the refrigerator, wait approximately 15-30 minutes to allow the LIFMIOR solution in the syringe to reach room temperature.
Ko brizgo vzamete iz hladilnika, počakajte približno 15 do 30 minut, da se raztopina zdravila LIFMIOR v brizgi segreje na sobno temperaturo.
The recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose) given twice weekly as a subcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of 50 mg per dose) given once weekly.
Priporočeni odmerek je 0,4 mg/kg telesne mase (do največ 25 mg na odmerek) 2-krat na teden v obliki subkutane injekcije z razmikom med odmerki od 3 do 4 dni ali 0,8 mg/kg (do največ 50 mg na odmerek) enkrat na teden.
• If you have any further questions, ask your doctor, pharmacist or nurse.
Če imate dodatna vprašanja, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Rates of serious adverse events and serious infections did not increase with long-term exposure.
Pri dolgotrajni izpostavljenosti zdravilu se delež resnih neželenih učinkov in hudih okužb ni povečal.
• The pre-filled syringe is for single-use administration only.
Napolnjena injekcijska brizga je namenjena le za enkratno uporabo.
Differences from adults and other special considerations are discussed in the following paragraphs.
Spodaj opisujemo razlike glede na odrasle bolnike in druge posebnosti.
Some vaccines, such as oral polio vaccine, should not be given while using LIFMIOR.
Med zdravljenjem z zdravilom LIFMIOR nekaterih cepiv, npr. peroralnega cepiva proti otroški paralizi, ni dovoljeno uporabljati.
Method and route of administration
Način in pot uporabe
NEVER re-cap a needle.
Na iglo NIKOLI ponovno ne nameščajte pokrovčka.